covid-19 vaccine infection

COVID-19 vaccine response weakened by common IBD drug

inflammatory bowel disease (IBD) may have limited protection after their first COVID-19 vaccine dose, according to a new study.The research found that people using the biologic drug infliximab (Remicade), which belongs to the anti-tumor necrosis factor (anti-TNF) class of drugs, had significantly lower antibody concentrations after their first dose of a COVID-19 vaccine than people using an alternative biologic called vedolizumab (Entyvio).

This drug has a different mode of action and belongs to the gut-specific integrin receptor antagonist class of drugs.However, in a subgroup of people who had previously had SARS-CoV-2, and in a few people who had already had a second vaccine dose, the antibody response increased significantly.Stay.

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News